Related Experiment Videos
Immunotherapy for colorectal cancer
1The Barrett Cancer Center, University of Cincinnati, 234 Goodman Avenue, Cincinnati, OH 45267-0502, USA. kenneth.foon@uc.edu
Current Oncology Reports
|March 20, 2001
Summary
Immunotherapy for colorectal cancer has advanced from general immune stimulants to targeted treatments. Current strategies focus on tumor-associated antigens using passive or active immune therapies.
Area of Science:
- Oncology
- Immunology
- Cancer Therapy
Background:
- Colorectal cancer (CRC) treatment has historically involved nonspecific immune stimulation.
- Nonspecific immune stimulants like bacillus Calmette-Guérin (BCG) were previously used.
- The field has shifted towards more targeted immunotherapeutic strategies for CRC.
Purpose of the Study:
- To review the evolution of immunologic approaches for colorectal cancer therapy.
- To highlight the shift from nonspecific to targeted immunotherapies.
- To categorize current active and passive immunotherapeutic strategies.
Main Methods:
- Review of historical and current immunologic therapies for colorectal cancer.
- Categorization of passive immunotherapy (e.g., antibody-based).
- Categorization of active immunotherapy (e.g., vaccination with tumor cells, lysates, peptides, carbohydrates, gene constructs, anti-idiotype antibodies).
Main Results:
- Immunotherapy for colorectal cancer has evolved significantly.
- Past treatments utilized nonspecific immune stimulants (e.g., BCG).
- Current focus is on targeting tumor-associated antigens.
Conclusions:
- Modern colorectal cancer immunotherapy centers on targeting tumor-specific antigens.
- Passive immunotherapy employs targeted antibodies.
- Active immunotherapy involves various vaccination strategies to elicit an immune response against tumor cells.